Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANX005 Safety and PK/PD in Healthy Volunteers
NCT03010046Phase 1Terminated
- Sponsor
- Annexon Biosciences
- Start
- Dec 2016
- Primary completion
- Jun 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tanruprubart in Guillain-Barré syndrome (GBS) (3 arms), sponsored by Annexon Biosciences. Primary endpoint: Number of subjects with treatment-related adverse events at Day 43. Started Dec 2016; status: terminated.
02
Drugs
tanruprubart
03
Conditions
Guillain-Barré syndrome (GBS)
Beyond the preview
Go deeper on NCT03010046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03010046.